10 VPs of market access
Vice President of Market Access and Vice President, Head of Market Access are among the current titles held by these VPs of market access at biotechnology and pharmaceutical companies. A reader can learn how VPs of market access approach their work from people who have held the role.
Professionals to explore
Brian Walls
LinkedInExperience: Vice President of Market Access · Spruce Biosciences
Brian Walls has been Vice President of Market Access at Spruce Biosciences since May 2026, based in Plano, Texas. Brian Walls was Vice President of Market Access at Applied Therapeutics from 2024 to 2025, Vice President, Market Access at Reata Pharmaceuticals from 2019 to 2023 and Executive Director, Pricing and Market Access at Progenics Pharmaceuticals from 2017 to 2019, and describes building and scaling rare and ultra-rare biopharmaceutical commercialization platforms.
Elisa Hennessy
LinkedInExperience: Vice President, Head of Market Access · Zenas BioPharma
Elisa Hennessy has been Vice President, Head of Market Access at Zenas BioPharma since March 2026, based in Wichita, Kansas, and describes building market access organizations covering pricing, contracting and reimbursement. Elisa Hennessy was Head of Market Access at Averitas Pharma from 2021 to 2025 and Senior Director, U.S. Market Access & Reimbursement at Lundbeck from 2020 to 2021.
Keith White
LinkedInExperience: Vice President, Market Access · Disc Medicine
Keith White has been Vice President, Market Access at Disc Medicine since June 2025, based in Brookline, New Hampshire. Keith White was Vice President, Value, Access and Pricing at X4 Pharma from 2024 to 2025, Head, Global Market Access at Amylyx Pharmaceuticals from 2020 to 2024 and Vice President and Head, Global Market Access at Corbus Pharmaceuticals from 2019 to 2020.
Kevin Clarke
LinkedInExperience: Vice President, Market Access & Trade · Neurotech Pharmaceuticals, Inc.
Kevin Clarke has been Vice President, Market Access & Trade at Neurotech Pharmaceuticals since May 2026, based in Manasquan, New Jersey. Kevin Clarke was Executive Director, Strategic Accounts & Access at Disc Medicine from 2025 to 2026 and Executive Director, US Market Access & Reimbursement at Alexion Pharmaceuticals from 2019 to 2025, with a focus on rare disease and specialty drug launches.
Nick Vigliarolo
LinkedInExperience: Vice President US Market Access · Revolution Medicines
Nick Vigliarolo has been Vice President US Market Access at Revolution Medicines since April 2025, based in Mantua, New Jersey, and describes establishing strategic pricing as the function that sets price strategy for senior leadership. Nick Vigliarolo was Executive Director, Pricing and Contracting at Ionis Pharmaceuticals from 2024 to 2025 and Executive Director, US Market Access and Pricing at Seagen from 2022 to 2024.
PJ Keith
LinkedInExperience: VP Global Market Access · Kyverna Therapeutics
PJ Keith has been VP Global Market Access at Kyverna Therapeutics since January 2026, based in Fall City, Washington. PJ Keith was VP, US Market Access at BioMarin Pharmaceutical from 2023 to 2026, Vice President, Payer and Organized Customer Sales at Bristol Myers Squibb from 2021 to 2023 and VP, Value and Access at Juno Therapeutics from 2017 to 2021.
Ranjani Manjunath Durham
LinkedInExperience: Vice President of Market Access · Innoviva Specialty Therapeutics, Inc.
Ranjani Manjunath Durham has been Vice President of Market Access at Innoviva Specialty Therapeutics since May 2026, based in West Chester, Pennsylvania. Ranjani Manjunath Durham was Head Pipeline & Early Commercial Strategy at Novo Nordisk from 2024 to 2026 and describes commercial experience across market access, marketing and health economics and outcomes research.
Reagan Klima
LinkedInExperience: Vice President, Market Access & Policy · Iovance Biotherapeutics, Inc.
Reagan Klima has been Vice President, Market Access & Policy at Iovance Biotherapeutics since October 2025, based in the Charleston, South Carolina area. Reagan Klima was Vice President, US Market Access (Gene Therapy, Rare Disease) at BioMarin in 2023 and Head of US Market Access for cell therapy at Kite Pharma from 2020 to 2021, with a focus on cell and gene therapy and oncology launches.
Robert Host
LinkedInExperience: Vice President Market Access · Stoke Therapeutics
Robert Host has been Vice President Market Access at Stoke Therapeutics since July 2026, based in the Denver area. Robert Host was Executive Director Market Access at Bristol Myers Squibb from 2024 to 2026, Executive Director Market Access at Karuna Therapeutics from 2022 to 2024 and Senior Director Market Access at BridgeBio from 2021 to 2022, and describes work across access strategy, policy and execution.
Shannon Hussey
LinkedInExperience: Vice President, Head of Market Access · Fennec Pharmaceuticals Inc
Shannon Hussey has been Vice President, Head of Market Access at Fennec Pharmaceuticals since April 2025, based in Peoria, Illinois. Shannon Hussey was Senior Director, US Market Access Strategy Hematology - Oncology at Sobi from 2023 to 2025 and Senior National Director US Market Access at CTI BioPharma from 2021 to 2023, and describes a background in the oncology market.
Choose the right perspective
Match the person's therapy areas and launch experience to your product, since rare disease, cell and gene therapy and oncology access work differ. Check when each person started the current role to judge how recent their view of payers is.
Questions to take into the conversation
- 01How do you build a market access team ahead of a first product launch?
- 02What evidence do payers ask for most when you negotiate coverage for a new therapy?
- 03How do you set launch pricing and contracting strategy with commercial leadership?
Reaching VPs of market access
How can I contact one of these VPs of market access?
Pick one of the 10 people on this page and choose "Book a paid call", or describe your project to find others. You offer a fee for a 15-minute call or a written answer, Instant Expert finds the person's work email and sends the invitation, and they decide whether to accept. The list covers 10 companies, including Spruce Biosciences, Zenas BioPharma and Disc Medicine, based on profile data retrieved on October 22, 2026. Being listed here doesn't mean someone has agreed to take calls.
How much does it cost to reach VPs of market access?
You choose the offer, starting at $5 per person. The offer is what the person receives, and Instant Expert's fee is added on top, so a $100 offer costs you $125. The fee is 20% of what you pay. You're charged only when the person books the call or sends the answer.
What if they don't reply?
You pay nothing. Instant Expert sends follow-up reminders, and if the person hasn't booked or answered within 7 days, the request expires and any hold on your card is released. You can invite several of the 10 people on this list at once and cap your total spend, so you pay only for the ones who accept.
Can an AI agent ask one of these VPs of market access a question?
Yes. An agent with a USDC wallet on Base can ask one question without an Instant Expert account. It names the person, for example by the LinkedIn URL on this page, and pays per ask over x402 (HTTP 402). The person answers in writing or by voice note, and if nobody answers within 7 days, the payment goes back to the wallet automatically. Claude and ChatGPT can do the same through the Instant Expert connector: setup is at /docs/mcp for Claude and /docs/chatgpt for ChatGPT. x402 docs
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.
Request a correction or removal